Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
04/2005
04/28/2005CA2540195A1 Amphiphilic [5:1]- and [3:3]- hexakisadducts of fullerenes
04/28/2005CA2535043A1 Process for preparing polysaccharide-protein conjugate vaccines
04/27/2005EP1526183A2 Dimer of a peptide derived from the C-terminal sequence of human superoxide dismutase facilitating the penetration of a substance into cells and/or cell nuclei
04/27/2005EP1526171A1 Simultaneous stimulation and concentration of cells
04/27/2005EP1525890A1 Protein-Proteophore complexes
04/27/2005EP1525889A1 Liquid pharmaceutical composition containing an erythropoietin derivative
04/27/2005EP1525884A1 Aqueous liquid preparations and light-stabilized aqueous liquid preparations
04/27/2005EP1525882A1 Administration form comprising an acid-labile active compound
04/27/2005EP1525858A1 High viscosity liquid controlled delivery system
04/27/2005EP1525478A2 SHIGA TOXIN B-SUBUNIT AS A VECTOR FOR TUMOR DIAGNOSIS AND DRUG DELIVERY TO GB sb 3 /sb EXPRESSING TUMORS
04/27/2005EP1525246A2 Polyamino acids functionalized by at least one hydrophobic group and the therapeutic applications thereof
04/27/2005EP1525224A1 Hyaluronic acid derivatives
04/27/2005EP1525002A1 Method for the synthesis of anthracycline-peptide conjugates
04/27/2005EP1525000A2 Gastrointestinal delivery of genetic material coupled to a transporting agent
04/27/2005EP1524999A1 Synthetic anti-candida albicans oligosaccharide based vaccines
04/27/2005EP1524998A1 Stable pharmaceutical composition comprising erythropoietin
04/27/2005EP1524997A1 Stable liquid parenteral parecoxib formulation
04/27/2005EP1524987A1 Nasal peptide pharmaceutical formulation
04/27/2005EP1524981A1 Sustained release formulations comprising lamotrigine
04/27/2005EP1524979A2 New effector conjugates, process for their production and their pharmaceutical use
04/27/2005EP1524975A1 Improved transdermal delivery system for the administration of rotigotine
04/27/2005EP1524974A2 Transcription factor modulating compounds and methods of use thereof
04/27/2005EP1524973A1 A pharmaceutical composition useful for treating chronic myeloid leukemia
04/27/2005EP1524971A1 Improved transdermal delivery system
04/27/2005EP1524969A2 Microcapsules with modified release of active principles with low solubility for oral delivery
04/27/2005EP1524967A1 Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
04/27/2005EP1524966A1 Taste masked oral composition of telithromycin
04/27/2005EP1299083B1 Implantable low molecular weight cellulosic compositions
04/27/2005EP1255445B1 Method of filtration of a dairy stream
04/27/2005EP1253932B1 Botulinum toxin pharmaceutical compositions
04/27/2005EP1217993B1 Bioadhesive nanoparticulate compositions having cationic surface stabilizers
04/27/2005EP1150707B1 USE OF AN OmpA ENTEROBACTERIUM PROTEIN ASSOCIATED WITH THE ELAGIGILTV PEPTIDE FOR TREATING MELANOMAS
04/27/2005EP1139974A4 Soy depigmenting and skin care compositions
04/27/2005EP1121153B1 Site-specific labeling of disulfide-containing targeting vectors
04/27/2005EP1105122B1 Pharmaceutical compositions containing lipase inhibitors
04/27/2005EP1073470B1 Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
04/27/2005EP0979072B1 Transdermal device for the delivery of testosterone
04/27/2005EP0939818B1 Recombinant toxin fragments
04/27/2005CN1610695A Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
04/27/2005CN1610694A Formulation of lymphokines and method of use thereof for local or bath local and systemic control of proliferative cell disorders
04/27/2005CN1610564A Compositions and methods of using collajolie
04/27/2005CN1610563A Hydrogenated castor oil dispersed in a lipid for pharmaceutically elegant topical ointments
04/27/2005CN1610560A Multivalent meningococcal polysaccharide-protein conjugate vaccine
04/27/2005CN1610559A Prostaglandin composition for the treatment of erectile dysfunction
04/27/2005CN1610558A Aspirin-containing transdermal pharmaceutical composition for the treatment of calcification
04/27/2005CN1610555A Eye drops
04/27/2005CN1610550A Pharmaceutical formulations comprising an immune response modifier
04/27/2005CN1610539A Pharmaceutical composition comprising a 5HT1 receptor agonist
04/27/2005CN1610538A Microemulsion preconcentrate
04/27/2005CN1610536A Composition in the form of an emulsion that can be used to treat plantar bromhidrosis and/or hyperhidrosis
04/27/2005CN1610506A Center-filled chewing gum containing calcium
04/27/2005CN1608683A Prepn of anticoagulant insoluble silk protein material
04/27/2005CN1608675A Medicine-carrying nanometer polymer particle and its prepn and use
04/27/2005CN1608674A Compound froctose injection and its medicine use
04/27/2005CN1198844C Process of high purity albumin production
04/27/2005CN1198659C Medical preparation, its preparing method and use in preparing medicine for accelerating collagen regeneration
04/27/2005CN1198655C Solid mixtures of cyclodextrins prep. via melt-extrusion
04/27/2005CN1198654C Pharmaceutical complex
04/27/2005CN1198652C Method for adding activated medicinal compounds into foundamental materials
04/27/2005CN1198650C Ocular tension lowering composition for topical administration
04/27/2005CN1198644C Human parathyroid hormone medicine composition
04/27/2005CN1198643C Insulin preparations containing carbohydrates
04/27/2005CN1198625C Pharmaceutical compositions for treatment of mucositis, stomatitis and Behchet's syndrome
04/27/2005CN1198623C Ciclesonide-containing aqueous pharmaceutical composition
04/27/2005CN1198620C Clathrates of dehydroepindrosterone and corresponding pharmaceutical compositions
04/27/2005CN1198616C Oral formulations for anti-tumor compounds
04/27/2005CN1198615C Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts of hydrates
04/27/2005CN1198611C Anti-bacterial medicinal compositions
04/27/2005CN1198609C Use of taxiol stabilized by albumin in preparing medicine for treating body tumor and medicine obtained therefrom
04/27/2005CN1198603C Spray liquid for forming bandage and drug delivery system
04/27/2005CN1198600C Edible MCC/PGA coating composition
04/27/2005CN1198598C Hydrophilic/lipophilic polymeric matrix dosage
04/27/2005CN1198596C Sustained release formulations for 24 hours release of metoprolol
04/27/2005CN1198592C Process for producing particles with converted amorphous and/or meta-stable drystalline region into crystalline state
04/27/2005CN1198591C Bioenhanced formulations comprising eprosartan in oral dosage form
04/27/2005CN1198590C Antibody and polyalkylene glycol-bonded liposome
04/27/2005CN1198589C Method for controlling liposome size
04/27/2005CN1198588C Multilayer emulsion for stabilization of effective component on dermatology and externally used preparation using it
04/27/2005CN1198587C Tear-gland specific emulsion for local application to eye tissue
04/27/2005CN1198586C Topical compositions for NSAI drug delivery
04/27/2005CN1198585C Effervescent ointment for vagina and rectum administration and its prepn
04/27/2005CN1198564C Cosmetic product
04/27/2005CN1198563C Acidified composition for topical treatment of nail and skin conditions
04/27/2005CN1198518C Composition comprising liquid absorbed on support based on precipitate silica
04/26/2005US6884882 Introducing an acetylene group at the 5-position of 2'-deoxyuridine, and reacting the formed intermediate 2'-deoxyuridine having the acetylene group at the 5-position, with a benzyl azide derivative
04/26/2005US6884874 Such as n-methyl-alanine derivatives; for preparing antibody/maytansinoid complexes
04/26/2005US6884817 Antitumor, anticancer agents; rheumatic diseases; autoimmune diseases
04/26/2005US6884797 Targeted oxidative therapeutic formulation
04/26/2005US6884794 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
04/26/2005US6884792 Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
04/26/2005US6884789 Containing an unoxidized and/or an oxidized cyclodextrin groups integrated into the polymer backbone; used as a delivery vehicle of various therapeutic agents; oxidation, amination
04/26/2005US6884778 Biocompatible macromers
04/26/2005US6884773 Modified hemoglobins, including nitrosylhemoglobins, and uses thereof
04/26/2005US6884768 Using taurine compound; adjust bioavailability; prevent, suppression damage to intestine mucous membrane
04/26/2005US6884437 Administration form comprising an acid-labile active compound
04/26/2005US6884433 Time release agents comprising drugs such as tacrolimus in solid solutions
04/26/2005US6884430 Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
04/26/2005US6884408 Delivery of diphenhydramine through an inhalation route
04/26/2005US6884288 A mixture comprising gum acacia, hydroxypropyl methylcellulose and propylene glycol plasticizer, forming a water solution to coat on drug tablets, food, and candy; long shelf life and low shipping costs
04/26/2005US6883516 Preparing solution of first component in liquid component such that after volatilization of liquid by passing solution through flow passage while heating, aerosol is formed having predetermined particle size distribution of first component